Fresenius Medical Care establishes regenerative medicine subsidiary

Published: 1-Jun-2016
Research & Development Pharmaceutical Cell & Gene Therapy

Unicyte will continue successful work with University of Turin into kidney and liver diseases, diabetes and cancer


Fresenius Medical Care, a provider of dialysis products and services, has created a new regenerative medicine subsidiary, called Unicyte, with its long-standing partner the University of Turin.

The new subsidiary will carry out research into kidney and liver diseases, diabetes and cancer.

Fresenius Medical Care has collaborated with the University of Turin since 2003. The first result of their joint research under the direction of Prof. Giovanni Camussi, Scientific Director of the university’s Torino Stem Cell Project, was the isolation and characterisation of a human stem cell population from an adult liver. These liver stem cells are said to be easy to isolate, are capable of being multiplied without limit and are transferrable into various other cell types, making them a potential option for regenerative medicine.

Further discoveries include functional pancreatic islets (which mimic the function of pancreatic cells) for the treatment of diabetes, and stem cell-derived extracellular vesicles (particles that support communication between cells) for the treatment of kidney and liver diseases as well as cancer. The first research results have recently been converted into preclinical development projects.

Following up on the successful partnership with Prof. Camussi, Unicyte will continue the joint research and pursue the development projects up to clinical studies on humans.

Dr Olaf Schermeier, Fresenius Medical Care’s CEO for Global Research and Development, said: 'We are very excited to be extending our successful collaboration with Prof. Camussi and the University of Turin. This is the right point in time to focus the outstanding scientific research on indications where there is great medical need.'

Florian Jehle, CEO of Unicyte and Vice President, Technology & Innovation Management at Fresenius Medical Care, added: 'The establishment of Unicyte is the logical step to translate the existing research collaboration on stem cells and extracellular vesicles into clinical programmes. In this way, Fresenius Medical Care is bundling its regenerative medicine research for selected indications.'

  • Companies:
  • Fresenius-Kabi
  • Unicyte
See more

You may also like

Cell & Gene Therapy

Fresenius Kabi and Cellular Origins partner to scale CGT manufacturing

Read more
Cellular Origins will provide its automated cell and gene therapy platform, Constellation, to the CMO, so customers can access 24/7 CGT manufacturing services

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  2. Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
  3. Theranexus and Exeltis sign commercialisation agreement for neurological disorder-targeting TX01 The therapeutic will be used to target Gaucher and Niemann-Pick type C, with Exeltis attaining the exclusive rights to the marketing and distribution of TX01 across the Europe, South America and the Middle East
  4. Novo Nordisk invests DKK 8.5bn into new Danish modular production site This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications
  5. Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Cell & Gene Therapy

Fresenius Kabi and Cellular Origins partner to scale CGT manufacturing

Cellular Origins will provide its automated cell and gene therapy platform, Constellation, to the CMO, so customers can access 24/7 CGT manufacturing services
Regulatory

Fresenius Kabi receives approval for tocilizumab biosimilar Tyenne

The Interleukin-6 antagonist can be used to treat various inflammatory and immune mediated conditions
Design & Build

Fresenius Kabi to invest $250 million to expand Melrose Park site in Illinois, US

Building work will start next year at generic injectables plant and will be completed in 2026
Finance

Fresenius Kabi expands IV drug business in Latin America

Deal builds on long-term presence in Brazil and creates a strong base for further expansion
Manufacturing

Fresenius Kabi receives warning letter from US FDA

FDA cites GMP non-conformities at Fresenius Kabi oncolytic API plant in Kalyani, India
Manufacturing

Modified starch coupled to therapeutic protein on industrial scale

The technology enables the modification of key pharmacological parameters
Manufacturing

Fresenius Kabi and Octapharma sign licensing agreement

<p>Fresenius Kabi of Germany and Swiss biopharmaceutical company Octapharma Group have signed a licensing agreement regarding the use of Fresenius Kabi\'s HESylation technology to develop a HESylated recombinant protein. </p>
Subscribe now